[144] CoreWeave, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 filed for CoreWeave, Inc. (CRWV) reporting a proposed sale of 250,000 common shares through Morgan Stanley Smith Barney with an aggregate market value of $25,760,000. The shares were originally acquired as founders' shares on 11/13/2017. The filing shows prior Rule 10b5-1 sales in August 2025 that sold a total of 1,250,000 shares for gross proceeds of $114,808,500. The company has 370,470,348 shares outstanding, and the planned sale is scheduled for 09/02/2025 on NASDAQ. The filer certifies no undisclosed material adverse information and references reliance on Rule 10b5-1 trading arrangements for recent sales.

Positive

• Clear regulatory disclosure of proposed sale including broker, share counts, and market value
• Use of Rule 10b5-1 trading plans for prior sales, which indicates prearranged, compliant selling
• Founders' shares acquisition date provided, improving transparency about provenance of securities

Negative

• Large insider selling in August 2025 (total 1,250,000 shares, $114.81M) may weigh on investor sentiment
• Proposed sale of $25.76M could be viewed negatively by some investors despite being a small percentage of outstanding shares

Insights

Securities Analyst

TL;DR: Substantial insider sales are disclosed but represent a small portion of total outstanding shares; disclosure and use of 10b5-1 plans reduce informational asymmetry.

The filing reports a proposed sale of 250,000 shares valued at $25.76M and documents 1.25M shares sold in August under 10b5-1 plans totaling $114.81M. Relative to 370.47M shares outstanding, cumulative recent sales are about 0.34% of the float, so direct dilution is limited. However, the size and timing of insider sales are material to investor sentiment. The clear identification of broker, acquisition date (founders' shares), and representation of no undisclosed material adverse facts supports regulatory compliance and transparency.

Risk & Compliance Specialist

TL;DR: The filing is routine and compliant; presence of dated 10b5-1 plans lowers legal risk but requires monitoring for coordinated insider dispositions.

Form 144 properly discloses the source of shares (founders' shares from 11/13/2017), broker details, planned sale date, and historical 10b5-1 executions. From a compliance perspective, documentation of trading plans and the signature attestation mitigate insider trading concerns. Investors should note that repeated large sales under 10b5-1 could still influence market perception despite procedural compliance.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	250000	25760000.00	370470348	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/13/2017	Founders Shares	Issuer			250000	11/13/2017	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for BRANNIN MCBEE 290 W Mt. Pleasant Ave. Livingston NJ 07039	Common	08/26/2025	250000	22996925.00
10b5-1 Sales for BRANNIN J. MCBEE 2022 IRR TRUST 290 W Mt. Pleasant Ave. Livingston NJ 07039	Common	08/26/2025	375000	34495387.50
10b5-1 Sales for BRANNIN MCBEE 290 W Mt. Pleasant Ave. Livingston NJ 07039	Common	08/19/2025	250000	22926475.00
10b5-1 Sales for BRANNIN J. MCBEE 2022 IRR TRUST 290 W Mt. Pleasant Ave. Livingston NJ 07039	Common	08/19/2025	375000	34389712.50

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for CoreWeave (CRWV) disclose?

The filing discloses a proposed sale of 250,000 common shares (aggregate market value $25,760,000) for sale on 09/02/2025 via Morgan Stanley Smith Barney and lists prior 10b5-1 sales in August 2025 totaling 1,250,000 shares and $114,808,500 gross proceeds.

When were the sold shares originally acquired?

The securities to be sold were acquired as founders' shares on 11/13/2017.

How large are these sales relative to CoreWeave's outstanding shares?

CoreWeave has 370,470,348 shares outstanding; the proposed 250,000-share sale equals about 0.07% of outstanding shares and recent August sales of 1,250,000 shares equal about 0.34%.

Were the prior sales conducted under an automatic trading plan?

Yes. The prior sales in August 2025 are labeled as 10b5-1 sales, indicating they were executed under prearranged trading plans.

Which broker is handling the proposed sale?

The broker listed is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, New York, NY.